OralDosed ingredientTherapeutic flag
Sorafenib Tosylate
CAS 284461-73-0
Sorafenib Tosylate (CAS 284461-73-0) is a Phase 4 pharmaceutical compound with 80 bioactivity targets and 602 adverse event associations.
SOURCE
NLM DailyMed
Label records
0
SOURCE
EMBL-EBI ChEMBL
Bioactivity
135
SOURCE
DrugCentral
Adverse signals
602
SOURCE
IUPHAR/BPS
PubMed IDs
24
SOURCE
EMBL-EBI ChEMBL
B25820EEF0F0
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Primary Name
Sorafenib Tosylate
CAS Number
284461-73-0
UNII
5T62Q3B36J
InChIKey
IVDHYUQIDRJSTI-UHFFFAOYSA-N
ChEMBL ID
CHEMBL1200485
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
sorafenibNexavar
dosed ingredientoraltherapeutic flag
SOURCE
EMBL-EBI ChEMBL
B25820EEF0F0
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL1200485 | Small molecule
SOURCE
EMBL-EBI ChEMBL
80 bioactivity rows
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| Mitogen-activated protein kinase 15 Kinase |
Kd | 7.34 | - | Homo sapiens |
| Tyrosine-protein kinase JAK3 Kinase |
Kd | 5.14 | - | Homo sapiens |
| 5-hydroxytryptamine receptor 1A GPCR |
Ki | 5.93 | - | Homo sapiens |
| 5-hydroxytryptamine receptor 2A GPCR |
Ki | 5.71 | - | Homo sapiens |
| 5-hydroxytryptamine receptor 2B GPCR |
Ki | 7.25 | - | Homo sapiens |
| 5-hydroxytryptamine receptor 2C GPCR |
Ki | 6.38 | - | Homo sapiens |
| 5-hydroxytryptamine receptor 6 GPCR |
Ki | 5.21 | - | Homo sapiens |
| 5-hydroxytryptamine receptor 7 GPCR |
Ki | 5.15 | - | Homo sapiens |
| ATP-binding cassette sub-family G member 2 Transporter |
IC50 | 5.51 | - | Homo sapiens |
| 5-hydroxytryptamine receptor 5A GPCR |
Ki | 5.48 | - | Homo sapiens |
| Platelet-derived growth factor receptor beta Kinase |
Kd | 7.43 | - | Homo sapiens |
| Tyrosine-protein kinase ABL1 Kinase |
Kd | 6.89 | - | Homo sapiens |
| Mast/stem cell growth factor receptor Kit Kinase |
Kd | 7.8 | - | Homo sapiens |
| Epidermal growth factor receptor Kinase |
IC50 | 8.53 | - | Homo sapiens |
| Carbonic anhydrase 7 Enzyme |
Ki | 5.09 | - | Homo sapiens |
| Proto-oncogene tyrosine-protein kinase Src Kinase |
IC50 | 6.41 | - | Homo sapiens |
| Tyrosine-protein kinase Lck Kinase |
Kd | 5.57 | - | Homo sapiens |
| Tyrosine-protein kinase Fyn Kinase |
Kd | 5.08 | - | Homo sapiens |
| Ephrin type-A receptor 2 Kinase |
Kd | 5.7 | - | Homo sapiens |
| RAF proto-oncogene serine/threonine-protein kinase Kinase |
Ki | 8.22 | - | Homo sapiens |
| Serine/threonine-protein kinase B-raf Kinase |
Ki | 7.66 | - | Homo sapiens |
| Receptor-type tyrosine-protein kinase FLT3 Kinase |
Kd | 8.35 | - | Homo sapiens |
| Proto-oncogene tyrosine-protein kinase receptor Ret Kinase |
Kd | 8.13 | - | Homo sapiens |
| Vascular endothelial growth factor receptor 1 Kinase |
Kd | 7.51 | - | Homo sapiens |
| Vascular endothelial growth factor receptor 2 Kinase |
Ki | 10.68 | - | Homo sapiens |
| Vascular endothelial growth factor receptor 3 Kinase |
Kd | 7.8 | - | Homo sapiens |
| Macrophage colony-stimulating factor 1 receptor Kinase |
Kd | 7.55 | - | Homo sapiens |
| Platelet-derived growth factor receptor alpha Kinase |
Kd | 7.21 | - | Homo sapiens |
| Receptor tyrosine-protein kinase erbB-2 Kinase |
IC50 | 6.88 | - | Homo sapiens |
| Cyclin-dependent kinase 2 Kinase |
Kd | 5.06 | - | Homo sapiens |
| Insulin receptor Kinase |
IC50 | 5.28 | - | Homo sapiens |
| Fibroblast growth factor receptor 3 Kinase |
Kd | 5.38 | - | Homo sapiens |
| Tyrosine-protein kinase HCK Kinase |
Kd | 5.07 | - | Homo sapiens |
| High affinity nerve growth factor receptor Kinase |
Kd | 5.44 | - | Homo sapiens |
| Myosin light chain kinase 2, skeletal/cardiac muscle Kinase |
Kd | 5.89 | - | Homo sapiens |
| Tyrosine-protein kinase CSK Kinase |
Kd | 5.54 | - | Homo sapiens |
| Angiopoietin-1 receptor Kinase |
Kd | 5.68 | - | Homo sapiens |
| Ephrin type-A receptor 8 Kinase |
Kd | 6.02 | - | Homo sapiens |
| Hepatocyte growth factor receptor Kinase |
IC50 | 5.24 | - | Homo sapiens |
| Tyrosine-protein kinase Lyn Kinase |
Kd | 5.52 | - | Homo sapiens |
| LIM domain kinase 1 Kinase |
Kd | 5.8 | - | Homo sapiens |
| Fibroblast growth factor receptor 1 Kinase |
Kd | 5.6 | - | Homo sapiens |
| Cyclin-dependent-like kinase 5 Kinase |
Kd | 5.21 | - | Homo sapiens |
| Serine/threonine-protein kinase 10 Kinase |
Kd | 6.85 | - | Homo sapiens |
| Serine/threonine-protein kinase PLK4 Kinase |
Kd | 5.47 | - | Homo sapiens |
| Aurora kinase C Kinase |
Kd | 6.68 | - | Homo sapiens |
| Dual specificity protein kinase TTK Kinase |
Kd | 5.46 | - | Homo sapiens |
| Abelson tyrosine-protein kinase 2 Kinase |
Kd | 5.89 | - | Homo sapiens |
| Mitogen-activated protein kinase 11 Kinase |
Kd | 6.7 | - | Homo sapiens |
| Ephrin type-A receptor 5 Kinase |
Kd | 6.44 | - | Homo sapiens |
SOURCE
DrugCentral
80 associations
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Palmar-plantar erythrodysaesthesia syndrome | 1783 | 6023.48 | 10033553 |
| Hepatic cancer | 392 | 1191.578 | 10073069 |
| Hepatic function abnormal | 607 | 1026.455 | 10019670 |
| Hepatic encephalopathy | 396 | 926.923 | 10019660 |
| Diarrhoea | 1855 | 839.333 | 10012735 |
| Decreased appetite | 993 | 695.098 | 10061428 |
| Ascites | 482 | 665.375 | 10003445 |
| Metastases to lung | 277 | 597.665 | 10027458 |
| Hypertension | 884 | 530.782 | 10020772 |
| Hepatic failure | 374 | 509.235 | 10019663 |
| Alpha 1 foetoprotein increased | 98 | 411.81 | 10001781 |
| Rash | 1033 | 296.815 | 10037844 |
| Amylase increased | 140 | 287.998 | 10002016 |
| Hepatocellular carcinoma | 129 | 277.418 | 10073071 |
| Drug ineffective | 270 | 273.962 | 10013709 |
| Dysphonia | 250 | 255.037 | 10013952 |
| Blood bilirubin increased | 256 | 253.254 | 10005364 |
| Blister | 353 | 228.246 | 10005191 |
| Hyperkeratosis | 107 | 216.209 | 10020649 |
| Skin exfoliation | 222 | 211.173 | 10040844 |
| Ammonia increased | 101 | 209.081 | 10001946 |
| Lipase increased | 131 | 207.644 | 10024574 |
| Skin toxicity | 102 | 192.524 | 10059516 |
| Jaundice | 199 | 191.095 | 10023126 |
| Liver carcinoma ruptured | 40 | 187.551 | 10050842 |
| Oesophageal varices haemorrhage | 70 | 162.729 | 10030210 |
| Infusion related reaction | 5 | 160.043 | 10051792 |
| Drug hypersensitivity | 18 | 159.569 | 10013700 |
| Dry skin | 212 | 153.691 | 10013786 |
| Rheumatoid arthritis | 4 | 151.165 | 10039073 |
| Platelet count decreased | 368 | 149.492 | 10035528 |
| Death | 839 | 144.694 | 10011906 |
| Hypophosphataemia | 111 | 141.135 | 10021058 |
| Arthropathy | 3 | 138.952 | 10003285 |
| Liver disorder | 203 | 136.788 | 10024670 |
| Contraindicated product administered | 3 | 131.859 | 10078504 |
| Off label use | 1130 | 131.308 | 10053762 |
| Stomatitis | 305 | 128.356 | 10042128 |
| Erythema multiforme | 96 | 127.455 | 10015218 |
| Acute myeloid leukaemia recurrent | 57 | 124.577 | 10059034 |
| Condition aggravated | 96 | 123.917 | 10010264 |
| Metastases to bone | 118 | 122.354 | 10027452 |
| Renal cell carcinoma | 69 | 120.4 | 10067946 |
| Joint swelling | 38 | 117.045 | 10023232 |
| Malignant neoplasm progression | 274 | 116.047 | 10051398 |
| Pain of skin | 88 | 115.06 | 10033474 |
| Portal vein thrombosis | 61 | 112.398 | 10036206 |
| Therapeutic product effect decreased | 5 | 111.458 | 10082201 |
| Completed suicide | 5 | 110.18 | 10010144 |
| Aspartate aminotransferase increased | 252 | 105.031 | 10003481 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
SOURCE
IUPHAR/BPS
19 interactions
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| KIT proto-oncogene, receptor tyrosine kinase KIT |
Inhibition | 7.170000076293945 pIC50 | 21613405 |
| KIT proto-oncogene, receptor tyrosine kinase KIT |
Inhibition | 7.170000076293945 pIC50 | 15466206 |
| fms related receptor tyrosine kinase 3 FLT3 |
Inhibition | 7.239999771118164 pIC50 | 15466206 |
| fms related receptor tyrosine kinase 3 FLT3 |
Inhibition | 7.480000019073486 pIC50 | 21613405 |
| kinase insert domain receptor KDR |
Inhibition | 7.230000019073486 pKd | 22037378 |
| kinase insert domain receptor KDR |
Inhibition | 7.050000190734863 pIC50 | 15466206 |
| kinase insert domain receptor KDR |
Inhibition | 7.050000190734863 pIC50 | 21613405 |
| B-Raf proto-oncogene, serine/threonine kinase BRAF |
Inhibition | 7.659999847412109 pIC50 | 15466206 |
| Raf-1 proto-oncogene, serine/threonine kinase RAF1 |
Inhibition | 8.220000267028809 pIC50 | 15466206 |
| TNNI3 interacting kinase TNNI3K |
Binding | 6.550000190734863 pKd | 18183025|15711537 |
| cyclin dependent kinase 19 CDK19 |
Inhibition | 6.989999771118164 pKd | 26502155 |
| cyclin dependent kinase 8 CDK8 |
Inhibition | 7.0 pKd | 26502155 |
| discoidin domain receptor tyrosine kinase 2 DDR2 |
Inhibition | 8.0 pIC50 | 23279183 |
| fibroblast growth factor receptor 1 FGFR1 |
Inhibition | 6.239999771118164 pIC50 | 21613405 |
| fibroblast growth factor receptor 1 FGFR1 |
Inhibition | 6.239999771118164 pIC50 | 15466206 |
| fms related receptor tyrosine kinase 4 Flt4 |
Inhibition | 7.699999809265137 pIC50 | 15466206 |
| platelet derived growth factor receptor beta Pdgfrb |
Inhibition | 7.239999771118164 pIC50 | 15466206 |
| platelet derived growth factor receptor beta PDGFRB |
Inhibition | 7.239999771118164 pIC50 | 21613405 |
| ret proto-oncogene RET |
Inhibition | 7.900000095367432 pIC50 | 23279183 |
SOURCE
PharmGKB
60 phenotype rows
Pharmacogenomics
Drug-gene phenotype annotations and evidence levels from PharmGKB-mapped rows.
UGT1A1 (PA420) UGT1A1*1, UGT1A1*28
UGT1A1 *1/*28 + *28/*28 are associated with increased exposure to sorafenib in people with Neoplasms as compared to UGT1A1 *1/*1.
Evidence: -; PMID 22307138
UGT1A1 (PA420) UGT1A1*1, UGT1A1*28
UGT1A1 *1/*28 + *28/*28 is associated with increased likelihood of treatment interruptions when treated with sorafenib as compared to UGT1A1 *1/*1.
Evidence: -; PMID 27533851
UGT1A1 (PA420) UGT1A1*1, UGT1A1*28
UGT1A1 *1/*28 + *28/*28 is associated with increased likelihood of Hyperbilirubinemia when treated with sorafenib as compared to UGT1A1 *1/*1.
Evidence: -; PMID 27533851
UGT1A1 (PA420) UGT1A1*1, UGT1A1*28
UGT1A1 *1/*28 is associated with increased risk of Hyperbilirubinemia when treated with sorafenib in people with Carcinoma, Hepatocellular.
Evidence: -; PMID 19672597
KDR (PA30086) rs2239702
Genotypes CT + TT are associated with decreased overall survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to genotype CC.
Evidence: -; PMID 26830973
ABCG2 (PA390) rs2231137
Genotype CT is associated with concentrations of sorafenib in people with Carcinoma, Hepatocellular as compared to genotype CC.
Evidence: -; PMID 28289864
NOS3 (PA254) rs1799983
Genotype GG is associated with decreased overall survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes GT + TT.
Evidence: -; PMID 27058899
ABCB1 (PA267) rs1045642
Genotypes AA + AG are associated with increased risk of Hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to genotype GG.
Evidence: -; PMID 26830973
VEGFA (PA37302) rs2010963
Genotypes CG + GG are associated with increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Renal Cell as compared to genotype CC.
Evidence: -; PMID 26830973
KDR (PA30086) rs2239702
Genotypes CT + TT are associated with decreased progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to genotype CC.
Evidence: -; PMID 26830973
ABCC2 (PA116) rs717620
Genotype CC is associated with increased risk of Exanthema when treated with sorafenib in people with Carcinoma, Renal Cell as compared to genotype CT.
Evidence: -; PMID 23237922
VEGFA (PA37302) rs3025040
Genotype CC is associated with increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes CT + TT.
Evidence: -; PMID 22736425
UGT1A1 (PA420) UGT1A1*1, UGT1A1*6
UGT1A1 *6 is not associated with risk of Exanthema when treated with sorafenib in people with Carcinoma, Renal Cell as compared to UGT1A1 *1/*1.
Evidence: -; PMID 23237922
UGT1A1 (PA420) UGT1A1*1, UGT1A1*28
UGT1A1 *28 is not associated with risk of Exanthema when treated with sorafenib in people with Carcinoma, Renal Cell as compared to UGT1A1 *1/*1.
Evidence: -; PMID 23237922
KDR (PA30086) rs2071559
Genotype GG is associated with decreased overall survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes AA + AG.
Evidence: -; PMID 25182707
KDR (PA30086) rs2305948
Genotype TT is associated with increased progression-free survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes CC + CT.
Evidence: -; PMID 25182707
VEGFA (PA37302) rs2010963
Genotype GG is associated with decreased overall survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes CC + CG.
Evidence: -; PMID 24510746
VEGFA (PA37302) rs833061
Genotype CC is associated with decreased progression-free survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes CT + TT.
Evidence: -; PMID 24510746
NOS3 (PA254) rs1799983
Genotype GG is associated with decreased progression-free survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes GT + TT.
Evidence: -; PMID 27058899
NOS3 (PA254) rs2070744
Genotype TT is associated with decreased progression-free survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes CC + CT.
Evidence: -; PMID 27058899
- rs4604006
Genotype CC is associated with decreased overall survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes CT + TT.
Evidence: -; PMID 24510746
KDR (PA30086) rs2071559
Genotype AA is associated with decreased overall survival and progression-free survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes AG + GG.
Evidence: -; PMID 24510746
FLT1 (PA28180) rs664393
Genotype TT is associated with decreased overall survival and progression-free survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes CC + CT.
Evidence: -; PMID 24510746
HIF1A (PA29283) rs11549465
Genotype CT is associated with decreased progression-free survival when treated with axitinib or sorafenib in people with Carcinoma, Renal Cell as compared to genotype CC.
Evidence: -; PMID 25816720
GALNT14 (PA134920089) rs9679162
Genotype GG is not associated with response to sorafenib in people with Liver Neoplasms as compared to genotypes GT + TT.
Evidence: -; PMID 31611591
GALNT14 (PA134920089) rs9679162
Genotype GG is associated with increased response to sorafenib in people with Hepatitis C and Liver Neoplasms as compared to genotypes GT + TT.
Evidence: -; PMID 31611591
NR1I2 (PA378) rs2472677
Genotype CT is associated with increased severity of Alopecia, Drug Toxicity, hand-foot syndrome and mucositis when treated with sorafenib in women with Thyroid Neoplasms.
Evidence: -; PMID 31967518
NR1I2 (PA378) rs3814055
Genotype CT is associated with increased severity of Alopecia, Drug Toxicity, hand-foot syndrome and mucositis when treated with sorafenib in women with Thyroid Neoplasms as compared to genotype CC.
Evidence: -; PMID 31967518
NR1I2 (PA378) rs10934498
Genotype AG is associated with increased severity of Alopecia, Drug Toxicity, hand-foot syndrome and mucositis when treated with sorafenib in women with Thyroid Neoplasms.
Evidence: -; PMID 31967518
UGT1A9 (PA419) rs3832043
Genotype T/del is associated with increased severity of Alopecia, Drug Toxicity, hand-foot syndrome and mucositis when treated with sorafenib in women with Thyroid Neoplasms as compared to genotype del/del.
Evidence: -; PMID 31967518
SOURCE
NLM RxNorm
10 name rows
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| Sorafenib | 495881 | SU | MTHSPL |
| SORAFENIB | 495881 | SU | MTHSPL |
| SORAFENIB TOSYLATE | 597744 | SU | MTHSPL |
| Sorafenib Tosylate | 597744 | SU | MTHSPL |
| sorafenib | 495881 | IN | RXNORM |
| SORAfenib | 495881 | TMSY | RXNORM |
| sorafenib tosylate | 597744 | PIN | RXNORM |
| SORAfenib tosylate | 597744 | TMSY | RXNORM |
| Nexavar | 619985 | BN | RXNORM |
| NexAVAR | 619985 | TMSY | RXNORM |
SOURCE
SIDER
80 side-effect rows
Side Effects
SIDER side-effect terms mapped to the drug or same-CAS compound identity.
| Side Effect | Drug Name | MedDRA Type | Concept ID |
|---|---|---|---|
| Abdominal discomfort | sorafenib | LLT | C0232487 |
| Abdominal discomfort | sorafenib | PT | C0232487 |
| Abdominal pain | sorafenib | LLT | C0000737 |
| Abdominal pain | sorafenib | PT | C0000737 |
| Abdominal pain lower | sorafenib | LLT | C0232495 |
| Abdominal pain lower | sorafenib | PT | C0232495 |
| Abdominal pain upper | sorafenib | LLT | C0232492 |
| Abdominal pain upper | sorafenib | PT | C0232492 |
| Abdominal rigidity | sorafenib | LLT | C0159066 |
| Abdominal rigidity | sorafenib | PT | C0159066 |
| Abdominal tenderness | sorafenib | LLT | C0232498 |
| Abdominal tenderness | sorafenib | PT | C0232498 |
| Acute coronary syndrome | sorafenib | PT | C0948089 |
| Acute interstitial nephritis | sorafenib | LLT | C0149937 |
| Alanine aminotransferase increased | sorafenib | LLT | C0151905 |
| Alanine aminotransferase increased | sorafenib | PT | C0151905 |
| Allergic cutaneous angiitis | sorafenib | LLT | C0151436 |
| Alopecia | sorafenib | LLT | C0002170 |
| Alopecia | sorafenib | PT | C0002170 |
| Amylase increased | sorafenib | LLT | C0151479 |
| Amylase increased | sorafenib | PT | C0151479 |
| Anaemia | sorafenib | LLT | C0002871 |
| Anaemia | sorafenib | PT | C0002871 |
| Anaphylactic shock | sorafenib | LLT | C0002792 |
| Anaphylactic shock | sorafenib | PT | C0002792 |
| Angioedema | sorafenib | LLT | C0002994 |
| Angioedema | sorafenib | PT | C0002994 |
| Angiopathy | sorafenib | LLT | C0042373 |
| Angiopathy | sorafenib | PT | C0042373 |
| Anorexia | sorafenib | LLT | C0003123 |
| Aphthous stomatitis | sorafenib | LLT | C0038363 |
| Aphthous stomatitis | sorafenib | PT | C0038363 |
| Arrhythmia | sorafenib | LLT | C0003811 |
| Arrhythmia | sorafenib | PT | C0003811 |
| Arthralgia | sorafenib | LLT | C0003862 |
| Arthralgia | sorafenib | PT | C0003862 |
| Ascites | sorafenib | LLT | C0003962 |
| Ascites | sorafenib | PT | C0003962 |
| Aspartate aminotransferase increased | sorafenib | LLT | C0151904 |
| Aspartate aminotransferase increased | sorafenib | PT | C0151904 |
| Asthenia | sorafenib | LLT | C0004093 |
| Asthenia | sorafenib | PT | C0004093 |
| Asthenia | sorafenib | PT | C0004093 |
| Blood and lymphatic system disorders | sorafenib | - | C0851353 |
| Blood bilirubin increased | sorafenib | LLT | C0311468 |
| Blood bilirubin increased | sorafenib | PT | C0311468 |
| Blood potassium decreased | sorafenib | PT | C0853761 |
| Blood pressure increased | sorafenib | LLT | C0497247 |
| Blood pressure increased | sorafenib | PT | C0497247 |
| Blood pressure systolic increased | sorafenib | LLT | C0277884 |
| Blood pressure systolic increased | sorafenib | PT | C0277884 |
| Blood thyroid stimulating hormone increased | sorafenib | PT | C0853019 |
| Body temperature increased | sorafenib | LLT | C0015967 |
| Body temperature increased | sorafenib | PT | C0015967 |
| Bone disorder | sorafenib | LLT | C0005940 |
| Bone disorder | sorafenib | PT | C0005940 |
| Brain cancer metastatic | sorafenib | LLT | C0220650 |
| Brain cancer metastatic | sorafenib | PT | C0220650 |
| Breast disorder | sorafenib | LLT | C0006145 |
| Breast disorder | sorafenib | PT | C0006145 |
| Burning mouth syndrome | sorafenib | LLT | C0006430 |
| Burning mouth syndrome | sorafenib | PT | C0006430 |
| Carcinoma | sorafenib | LLT | C0007097 |
| Cardiac disorder | sorafenib | LLT | C0018799 |
| Cardiac disorder | sorafenib | PT | C0018799 |
| Cardiac failure | sorafenib | LLT | C0018801 |
| Cardiac failure | sorafenib | PT | C0018801 |
| Cardiac failure congestive | sorafenib | LLT | C0018802 |
| Cardiac failure congestive | sorafenib | PT | C0018802 |
| Cerebral haemorrhage | sorafenib | LLT | C2937358 |
| Cerebral haemorrhage | sorafenib | PT | C2937358 |
| Cholangitis | sorafenib | LLT | C0008311 |
| Cholangitis | sorafenib | PT | C0008311 |
| Cholecystitis | sorafenib | LLT | C0008325 |
| Cholecystitis | sorafenib | PT | C0008325 |
| Completed suicide | sorafenib | PT | C0852733 |
| Connective tissue disorder | sorafenib | LLT | C0009782 |
| Connective tissue disorder | sorafenib | PT | C0009782 |
| Constipation | sorafenib | LLT | C0009806 |
| Constipation | sorafenib | PT | C0009806 |
SOURCE
Rendered pharma page rows
FAQPage JSON-LD
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Sorafenib Tosylate used for in pharmaceutical contexts?
Sorafenib Tosylate (CAS 284461-73-0) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Sorafenib Tosylate?
Sorafenib Tosylate has 602 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Palmar-plantar erythrodysaesthesia syndrome, Hepatic cancer, Hepatic function abnormal, Hepatic encephalopathy, Diarrhoea. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Sorafenib Tosylate also used in cosmetics?
No same-CAS cosmetics profile is rendered from the ingredients-table cross-reference for Sorafenib Tosylate.
What clinical phase is Sorafenib Tosylate in?
Sorafenib Tosylate is rendered with ChEMBL max phase 4 (approved).
What bioactivity targets are documented for Sorafenib Tosylate?
Sorafenib Tosylate has 135 bioactivity rows in this page query. Rendered target entries include Mitogen-activated protein kinase 15, Tyrosine-protein kinase JAK3, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B.